Company Analysis ACADIA Pharmaceuticals Inc.
1. Summary
Advantages
- The stock's return over the last year (84.12%) is higher than the sector average (-2.93%).
- Current debt level 4.38% is below 100% and has decreased over 5 years from 6.33%.
Disadvantages
- Price (27.55 $) is higher than fair price (22.91 $)
- Dividends (0%) are below the sector average (0.5317%).
- The company's current efficiency (ROE=38.89%) is lower than the sector average (ROE=106.63%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| ACADIA Pharmaceuticals Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 1.4% | -14.5% | 0.1% |
| 90 days | 28.8% | -5.6% | 4.6% |
| 1 year | 84.1% | -2.9% | 20.5% |
ACAD vs Sector: ACADIA Pharmaceuticals Inc. has outperformed the "Healthcare" sector by 87.06% over the past year.
ACAD vs Market: ACADIA Pharmaceuticals Inc. has outperformed the market by 63.58% over the past year.
Stable price: ACAD is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ACAD with weekly volatility of 1.62% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (27.55 $) is higher than the fair price (22.91 $).
Price is higher than fair: The current price (27.55 $) is 16.8% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (12.26) is lower than that of the sector as a whole (33.49).
P/E vs Market: The company's P/E (12.26) is higher than that of the market as a whole (-68.72).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (3.79) is lower than that of the sector as a whole (260.15).
P/BV vs Market: The company's P/BV (3.79) is lower than that of the market as a whole (51.39).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (2.9) is lower than that of the sector as a whole (129.83).
P/S vs Market: The company's P/S indicator (2.9) is lower than that of the market as a whole (148.63).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (25.05) is higher than that of the sector as a whole (-28.84).
EV/Ebitda vs Market: The company's EV/Ebitda (25.05) is higher than that of the market as a whole (-95.22).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -46.96% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-46.96%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-598.11%).
6.4. ROE
ROE vs Sector: The company's ROE (38.89%) is lower than that of the sector as a whole (106.63%).
ROE vs Market: The company's ROE (38.89%) is higher than that of the market as a whole (-6.23%).
6.6. ROA
ROA vs Sector: The company's ROA (23.39%) is higher than that of the sector as a whole (-2.32%).
ROA vs Market: The company's ROA (23.39%) is lower than that of the market as a whole (38.59%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-37.11%) is lower than that of the sector as a whole (0.8343%).
ROIC vs Market: The company's ROIC (-37.11%) is lower than that of the market as a whole (9.66%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5317%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 02.05.2025 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER |
Sale | 14.6 | 51 071 | 3 498 |
| 02.05.2025 | Kihara James PRINCIPAL ACCOUNTING OFFICER |
Sale | 14.6 | 19 374 | 1 327 |
| 08.04.2025 | Kihara James PRINCIPAL ACCOUNTING OFFICER |
Sale | 14.82 | 15 235 | 1 028 |
| 08.04.2025 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER |
Sale | 14.82 | 40 133 | 2 708 |
| 26.03.2025 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER |
Sale | 17.05 | 54 066 | 3 171 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
